Application deadline for Fibromyalgia clinical trial set

By Website Administrator | Jun 7, 2002

Applications for the Fibromyalgia treatment clinical trial at McLaren Regional Medical Center in Flint in conjunction with Kettering University will be accepted until Aug. 1.

Applications for the Fibromyalgia treatment clinical trial at McLaren Regional Medical Center in Flint in conjunction with Kettering University will be accepted until Aug. 1. Research applications can be found on the Internet at www.fm-research.com, or can be obtained by calling (810) 762-9791.

Dr. Jeff Hargrove, assistant professor of Mechanical Engineering at Kettering University, has worked with specialists in Washington, D.C., and Atlanta to develop a diagnostic tool and viable course of treatment for Fibromyalgia and myofascial pain patients. Hargrove, Dr. Susan Smith and Dr. Sunil Nagpal, directors of the Internal Medicine residency program at McLaren Regional Medical Center, in Flint, will conduct a clinical trial for the treatment.

The trial, only the second such trial in the country, will be a double-blind, placebo-controlled clinical trial to study the effects of cranial neurostimulation on Fibromyalgia patients, including the effect on myofascial trigger points relating to muscle pain symptoms. Funding for the trial will be provided by the McLaren Foundation and Kettering University.

"We are looking for 160 people between the ages of 18 and 62, who have been diagnosed as having Fibromyalgia using the American College of Rheumatology (ACR) 1990 criteria," said Hargrove.

The ACR 1990 criteria uses 18 prescribed tender points on the body to indicate excessive pain caused by fibromyalgia. "A patient must have 11 of 18 tender points to be diagnosed with fibromyalgia," Hargrove said. Participants must be able to receive 22 treatments at McLaren over a period of about 11 weeks.

Fibromyalgia patients are encouraged to apply before the Aug. 1 deadline, even if they are not sure they would qualify, or are not certain if they could participate due to distance. Once their application is on file, patients will be included in a confidential database. The database allows researchers to communicate information about new research findings that may be useful to all patients, or when a new study forms that may be of importance to patients not involved in the Flint trial.

The researchers at McLaren and Kettering are constantly developing other research relationships and studies to examine other aspects of Fibromyalgia and chronic pain conditions.

For more information: www.fm-research.com